NanoTx has reached an agreement with Plus Therapeutics for the licensing and development of Rhenium Nanoliposomes:
NanoTx has received a New Company award notice from the Cancer Prevention and Research Institute of Texas (CPRIT). Please see CPRIT's website here.
The first in human study for RNL is now underway:
Please check back periodically for additional news as the study progresses....
NanoTx Therapeutics © ALL RIGHTS RESERVED.